Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. by Oakeshott, P et al.
RESEARCH
Randomised controlled trial of screening for Chlamydia
trachomatis to prevent pelvic inflammatory disease: the
POPI (prevention of pelvic infection) trial
Pippa Oakeshott, reader in general practice,1 Sally Kerry, senior lecturer in medical statistics,1
Adamma Aghaizu, research assistant,1 Helen Atherton, doctoral student,2 Sima Hay, lecturer in midwifery,3
David Taylor-Robinson, professor emeritus,4 Ian Simms, epidemiologist,5 Phillip Hay, reader in genitourinary
medicine6
ABSTRACT
Objective To determine whether screening and treating
women for chlamydial infection reduces the incidence of
pelvic inflammatory disease over the subsequent
12 months.
Design Randomised controlled trial.
Setting Common rooms, lecture theatres, and student
bars at universities and further education colleges in
London.
Participants 2529 sexually active female students, mean
age 21 years (range 16-27).
Intervention Participants completed a questionnaire and
provided self taken vaginal swabs, with follow-up after
one year. Samples were randomly allocated to immediate
testing and treatment for chlamydial infection, or storage
and analysis after a year (deferred screening controls).
Main outcome measure Incidence of clinical pelvic
inflammatory disease over 12 months.
Results Baseline prevalence of chlamydia was 5.4%
(68/1254) in screened women and 5.9% (75/1265) in
controls. 94% (2377/2529) of women were followed up
after 12 months. The incidence of pelvic inflammatory
disease was 1.3% (15/1191) in screened women
compared with 1.9% (23/1186) in controls (relative risk
0.65, 95% confidence interval 0.34 to 1.22). Seven of 74
control women (9.5%, 95% confidence interval 4.7% to
18.3%) who tested positive for chlamydial infection at
baseline developed pelvic inflammatory disease over
12 months compared with one of 63 (1.6%) screened
women (relative risk 0.17, 0.03 to 1.01). However, most
episodes of pelvic inflammatory disease occurred in
women who tested negative for chlamydia at baseline
(79%, 30/38). 22% (527/2377) of women reported being
tested independently for chlamydia during the trial.
Conclusion Although some evidence suggests that
screening for chlamydia reduces rates of pelvic
inflammatory disease, especially in women with
chlamydial infection at baseline, the effectiveness of a
single chlamydia test in preventing pelvic inflammatory
disease over 12 months may have been overestimated.
Trial registration ClinicalTrials.gov NCT00115388.
INTRODUCTION
Genital infectionwithChlamydia trachomatis is themost
common bacterial sexually transmitted infection in the
United States and Europe, with over threemillion new
infections diagnosed each year.1 2 But most chlamydial
infections remain asymptomatic and undiagnosed.3
Untreated chlamydial infection in women can lead to
pelvic inflammatory disease, causing scarring of the
fallopian tubes, which can result in tubal infertility,
chronic pelvic pain, and ectopic pregnancy. The
annual cost of chlamydial infection and its sequelae in
the United States has been estimated to exceed $2bn.2
In many developed countries, screening pro-
grammes for chlamydia have been set up to reduce
transmission and reproductive tract morbidity.2 The
US Centers for Disease Control and Prevention
recommend annual screening of all sexually active
women aged 25 or less.1 In England the recommenda-
tion applies towomen aged 24or less.2 But controversy
remains about the evidence base. The results of the
landmark trial by Scholes et al4 have been
questioned,5-7 and the continuing search for supporting
evidence from other randomised controlled trials and
epidemiological studies has not been always fruitful.8-11
The UK National Institute for Health and Clinical
Excellence recommended improvements in the qual-
ity of randomisation, allocation concealment, and
blinding of assessment of outcome in any future trials
of chlamydia screening.3 A more accurate estimate of
the rate of progression of genital chlamydial infection
to pelvic inflammatory disease is also urgently needed
to evaluate the cost effectiveness of screening
programmes.12 However, neither of the two previous
trials4 9 tested all the control women. No trials of
chlamydia screening have taken place in a British
population.
The national chlamydia screening programme was
progressively rolled out across England from 2003 to
2008. This left a window of opportunity from 2004 to
2007 to carry out a community based trial in a non-
healthcare setting using self taken samples. In the
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POPI (prevention of pelvic infection) trial we investi-
gated whether screening young sexually active female
students for chlamydial infection and treating those
found to be infected reduced the incidence of pelvic
inflammatory disease in the subsequent 12 months.
We also carried out an exploratory study to investigate
the incidence of pelvic inflammatory disease inwomen
with untreated chlamydial infection.13
METHODS
The design and recruitment methods have been pub-
lished elsewhere.13-15 Briefly, women were eligible for
inclusion if theywere aged 27 or less andwere sexually
active.We excludedwomenwhohad never had sexual
intercourse, hadbeen tested for chlamydial infection in
the past three months, or were pregnant. Female
nurses, research assistants, the principal investigator
(PO), and peers recruited women in bars, common
rooms, and lecture theatres at 20 London universities
and further education colleges. (Further education col-
leges take students from age 16 and teach both aca-
demic subjects and vocational subjects, such as
hairdressing.)
Participants provided written informed consent.13
They were warned of the risks of chlamydial infection
and that their samples might not be tested for a year
and were advised to get checked independently if
they thought they had been at risk.
Procedures
Participants were asked to complete a brief confiden-
tial questionnaire on sexual health; to provide self
taken vaginal samples in the nearest lavatory; and to
allow access to their medical records, with follow-up
after a year.13Within two weeks of recruitment we ran-
domly allocated sealed sample packs, which contained
the completed, unopened questionnaires and consent
forms, into two groups using random number tables.
Vaginal swabs frompacks allocated to the intervention
group were tested for C trachomatis using transcription
mediated amplification (TMA;Gen-Probe, SanDiego,
CA). Vaginal swabs from packs allocated to deferred
screening were stored at −80°C and analysed one year
later. PO contacted infected women within two weeks
of diagnosis and asked them to attend their local geni-
tourinary medicine clinic or general practitioner for
treatment and partner notification. Vaginal smears
made at baseline were Gram stained and examined
for bacterial vaginosis using Nugent’s criteria.16 17
A year after recruitment, we asked the participants to
complete a secure online questionnaire about possible
symptoms of pelvic inflammatory disease (pelvic pain,
dyspareunia, bleeding between menstrual periods, or
abnormal vaginal discharge) and sexual behaviour
during the past year. Those who did not respond or
provide an email address were sent the questionnaire
by post, backed up by telephone reminders. We fol-
lowed up non-responders through their general prac-
tice records. For all women (or their general
practitioner) who reported that during the past
12months theyhadhad treatment for pelvic inflamma-
tory disease, had a laparoscopy, seen a health profes-
sional for abdominal or pelvic pain, been treated for a
urinary tract infection, or reported three of four possi-
ble symptoms of pelvic inflammatory disease, we
endeavoured to obtain copies of the clinical findings
from medical records of general practitioners, hospi-
tals, family planning clinics, and genitourinary medi-
cine clinics. After anonymisation of data, three
genitourinary doctors blinded to group allocation and
baseline chlamydia status used modified Hager’s
criteria18 and Centers for Disease Control guidelines1
to classify cases into probable, possible, or not pelvic
inflammatory disease.13 Cases were categorised inde-
pendently by two doctors, with review by a third for
disagreements.
Masking
Participants were blind to group allocation except for
those in the intervention group with baseline samples
that tested positive for chlamydia and who were
referred for treatment, and 38 women with indetermi-
nate test results who were asked to post a repeat sam-
ple. Investigators were blind during recruitment and
follow-up except PO when she referred women with
chlamydial infection for treatment. Categorisation of
pelvic inflammatory disease status was also blind.13
Statistical analysis
Assuming a 2% incidence of pelvic inflammatory dis-
ease in the control group, we needed a sample of 4122
women to detect a relative risk of 0.48 with 80% power
and 5% significance. We had difficulty with
recruitment,14 15 however, as we were asking women
who were not attending college for health reasons to
provide vaginal samples that might not be tested for a
year. Two studies9 19 suggested a higher rate of pelvic
inflammatory disease, enabling us to revise down our
sample size calculations. Assuming a 3% incidence of
pelvic inflammatorydisease in the control group,9 19we
Deferred screening control group (n=1270)
(samples frozen at -80 °C for 12 months)
Screened group (n=1259)
Chlamydia positive (n=68)
Referred for treatment and partner notification
  (n=65)
Women enrolled and provided vaginal samples; sealed sample packs also containing consent
forms and baseline questionnaires were randomly allocated into two groups (n=2563)
Followed up by questionnaire or general practice
  record search after 12 months (n=1191, 95%)
Selected for additional medical record search
  (n=218)
Reported being tested independently for
  chlamydia (n=269)
Followed up by questionnaire or general practice
  record search after 12 months (n=1186, 93%)
Selected for additional medical record search
  (n=178)
Reported being tested independently for
  chlamydia (n=258)
Excluded (n=20):
  Age >27 years (n=6)
  Never been sexually active (n=7)
  No swab provided (n=4)
  Enrolled twice (n=3)
Excluded (n=14):
  Age >27 years (n=6)
  Never been sexually active (n=3)
  No swab provided (n=3)
  Enrolled twice (n=2)
Lost to follow-up (3 withdrew) (n=68) Lost to follow-up (5 withdrew) (n=84)
Trial profile
RESEARCH
page 2 of 7 BMJ | ONLINE FIRST | bmj.com
needed a sample of 2274 women to detect a relative
risk of 0.44413 with 80% power and 5% significance.
Recruiting 2500 women allowed for 10% loss to fol-
low-up.
For the primary analysis we estimated the relative
risk of developing pelvic inflammatory disease in the
12 months after recruitment to the screened group
compared with the deferred screening control group.
In secondary analyses we examined the proportion of
control women with untreated chlamydial infection
who developed pelvic inflammatory disease within
12 months. We used exact methods to compute confi-
dence intervals for unadjusted relative risks.20 To
adjust the relative risk of pelvic inflammatory disease
for symptoms at baseline we also carried out an
exploratory binomial regression using Stata version
10. Thirty five samples randomly allocated to the
screening groupwere unintentionally put in the freezer
and not tested for C trachomatis for 12 months. All par-
ticipants were, however, analysed according to their
original group allocation.
RESULTS
Between September 2004 and October 2006, 2563 eli-
gible women were recruited and randomised (figure).
We were unable to obtain information on all non-par-
ticipants, but recruitment forms completed early in the
study suggested 41% of 956 ineligible women had
never had sexual intercourse, 24% were outside the
age range, and 13% had been tested for chlamydial
infection in the previous threemonths.13 A survey dur-
ing three recruitment sessions suggested that eligible
women refusing to participate were more likely than
responders to be from ethnic minority groups.15 After
34 exclusions (figure), 2529 women (mean age
20.9 years) were included in the study. Baseline char-
acteristics of participants were similar between the
screened and deferred screening groups except that
more women in the screened group reported symp-
toms in the six months before recruitment (table 1).
Chlamydial infection and treatment at baseline
Sixty eight (5.4%) women in the screened group tested
positive for chlamydia at baseline. PO contacted 65 of
the women to ask them to attend their local genitour-
inary medicine clinic or general practitioner for treat-
ment and partner notification. Two women could not
be contacted directly as their mobile telephone num-
ber was not working, they did not provide an email
address, and they had requested no post to the home
address. The college nurses contacted them for us. A
further chlamydia positive sample from the 35 inter-
vention samples unintentionally put in the freezer
was not tested for 12 months. When telephoned after
1-2 months, 59 women confirmed they had been trea-
ted: 36 at a genitourinary medicine clinic, 12 by their
general practitioner, and three at a community sexual
health clinic. Eight women did not provide details.
When control samples were tested 12 months after
recruitment, 75 (5.9%) were positive for chlamydia.
Table 1 | Baseline characteristics of 2529 women allocated to immediate or deferred
screening for Chlamydia trachomatis. Values are percentages (numbers) unless stated
otherwise
Characteristics
Screened women
(n=1259)
Deferred screening controls
(n=1270)
Age (years):
<20 44.2 (557) 44.6 (567)
20-24 46.5 (585) 43.3 (550)
≥25 9.3 (117) 12.0 (153)
Ethnicity: n=1250 n=1262
White 63.0 (787) 60.1 (758)
Black Caribbean 8.5 (106) 9.5 (120)
Black African 15.3 (191) 17.4 (220)
Black other 2.3 (29) 1.7 (22)
South Asian 3.0 (35) 2.8 (35)
Chinese 1.0 (11) 0.7 (9)
Other 7.3 (91) 7.8 (98)
Recruited at university* 69.5 (875) 66.7 (847)
Cigarettes smoked per day: n=1253 n=1265
None 66.9 (838) 69.9 (884)
1-10 26.6 (333) 24.0 (304)
>10 6.5 (82) 6.1 (77)
Mean (SD) age at sexual debut 16.4 (1.8); n=1233 16.5 (1.8); n=1247
No of sexual partners in past year: n=1251 n=1262
None 3.4 (42) 4.2 (53)
1 52.0 (650) 54.6 (689)
2 23.1 (289) 21.2 (268)
>2 21.6 (270) 20.0 (252)
Contraception: n=1243 n=1260
None 7.6 (95) 8.0 (101)
Condoms 53.4 (664) 55.2 (695)
Contraceptive pill 49.1 (610) 46.4 (585)
Implant, injection, or patch 5.1 (63) 5.3 (67)
Coil 1.7 (21) 1.7 (22)
Douching 0.2 (2) 0 (2)
Symptoms in past 6 months: n=1242 n=1254
Pelvic pain 13.7 (170) 11.8 (148)
Dyspareunia 13.1 (163) 10.0 (125)
Bleeding between menstrual
periods
14.1 (175) 11.3 (142)
Abnormal vaginal discharge 12.6 (157) 10.7 (134)
Any symptoms 36.6 (455) 31.3 (393)
Reported history of sexually
transmitted infection ever:
n=1190 n=1219
Chlamydia 5.9 (70) 6.6 (80)
Genital warts 1.2 (14) 1.2 (15)
Genital herpes 0.6 (7) 0.9 (11)
Bacterial vaginosis 0.9 (11) 0.5 (6)
Gonorrhoea 0.3 (4) 0.2 (2)
Reported history of pelvic
inflammatory disease:
n=1252 n=1265
2.1 (26) 0.9 (12)
Baseline infections:
Chlamydia† 5.4 (68); n=1254 5.9 (75); n=1265
Bacterial vaginosis 20 (241); n=1191 21 (248); n=1193
*Not further education colleges.
†No results were available for 10 baseline samples (five intervention, five control). Three intervention samples
were indeterminate or inhibitory and participants failed to return a repeat baseline postal sample, four samples
leaked, and three control samples were either lost or the labels were illegible after defrosting.
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Follow-up
Overall, 94% (2377/2529) of thewomenwere followed
up after 12 months. Nearly half (47%, 1108) replied by
email, 32% (n=760) by postal questionnaire, 8%
(n=199) by telephone, and 13% (n=310) were followed
up by questionnaire to their general practitioner. The
152 women lost to follow-up were younger (mean age
20.0 years (SD 2.5) v 21.0 (SD 2.8); P<0.01) and more
likely to be of black ethnicity (46% (68/149) v 26%
(620/2363); P<0.01) than the remainder. Table 2
gives details of the 396 women who were selected, on
the basis of questionnaire responses, for more detailed
assessment and search of medical records.
Incidence of pelvic inflammatory disease
The incidenceof pelvic inflammatorydiseasewas 1.3%
(15/1191) in screened women compared with 1.9%
(23/1186) in controls (relative risk 0.65, 95% confi-
dence interval 0.34 to 1.22, table 3). After adjustment
for symptoms at baseline the relative risk was 0.57
(0.29 to 1.11). The overall incidence of pelvic inflam-
matory disease over 12 months was 1.6% (38/2377,
95% confidence interval 1.1% to 2.1%).
Rates of pelvic inflammatory diseasewere examined
in the 137womenwith chlamydial infection at baseline
who were followed up for 12 months. Seven of 74
women in the deferred screening group developed
clinical pelvic inflammatory disease (incidence 9.5%,
4.7% to 18.3%). All seven women were tested for C
trachomatis at the time pelvic inflammatory disease
was diagnosed and five tested positive. By comparison,
only one of 63 (1.6%) screened and treated women
positive for chlamydia developed clinical pelvic
inflammatory disease (relative risk 0.17, 0.03 to 1.01).
Initial treatment for chlamydial infection in this
womanwas confirmedby telephonebut shedeveloped
symptoms of pelvic inflammatory disease and tested
positive for chlamydia 26 weeks after recruitment.
On the 12month questionnaire she reported three sex-
ual partners in the previous year and no use of con-
doms.
Most cases of pelvic inflammatory disease (79%,
30/38) occurred in women who tested negative for
chlamydia at baseline. Chlamydia test results at the
time pelvic inflammatory disease was diagnosed were
available for 26 (of 38) women, of whom16 tested posi-
tive for chlamydial infection. Ten of these 16 women
were negative for chlamydia at baseline. Seventy per
cent (21/30) of women with pelvic inflammatory dis-
ease who completed the 12 months’ questionnaire
reported having had two or more sexual partners dur-
ing the year. The groups showed a slight imbalance for
reported symptoms but similar sexual behaviour dur-
ing the follow-up period (table 4).
Independent testing during follow-up
Overall, 527 (22%) participants reported having been
tested independently for chlamydia (figure); 15%
(n=38) of the control women and 10% (n=27) of the
screened women said they tested positive. Those
women in the deferred screening group (blind to
group allocation and baseline chlamydia status) who
Table 2 | Details of follow-up for potential pelvic inflammatory disease (PID) over 12 months. Values are numbers unless
stated otherwise
Variables
Screened women
(n=1259)
Deferred screening
controls (n=1270)
% (No) followed up by questionnaire to participant or general practitioner 94.6 (1191) 93.4 (1186)
% (No) selected for additional record search for clinical details of potential PID: 17.3 (218) 14.0 (178)
Participant or general practitioner reported PID* 12 9
Laparoscopy 16 24
Visited doctor for abdominal or pelvic pain 108 95
Treated for urinary tract infection 50 22
Reported 3 of 4 symptoms† but did not report seeing doctor 32 28
*Some participants were in more than one category, but each is included only once, in hierarchical order.
†Pelvic pain, dyspareunia, bleeding between menstrual periods, or abnormal vaginal discharge.
Table 3 | Incidence of pelvic inflammatory disease (PID) in 2377 women followed up for 12 months. Values are percentages
(numbers) unless stated otherwise
Variables
Screened
women
Deferred screening
controls
Relative risk
(95% CI) P value
All PID: probable* and possible† 1.3 (15/1191) 1.9 (23/1186) 0.65 (0.34 to 1.22) 0.19
Probable PID 0.8 (10/1191) 1.3 (16/1186) 0.62 (0.29 to 1.34) 0.24
Rate of PID in women who were
positive for chlamydia at baseline
1.6 (1/63) 9.5 (7/74) 0.17 (0.03 to 1.01) 0.07
*Doctor assessed as probable—that is, clinical diagnosis of PID and treated1; modified Hager’s criteria—pelvic pain, cervical motion tenderness,
uterine or adnexal tenderness.18
†Abdominal pelvic pain with features of PID, which may have responded to antimicrobial therapy, but no record of cervical excitation or uterine or
adnexal tenderness; or long standing abdominal pain consistent with endometriosis, but some features of PID—for example, uterine tenderness, and
unable to confirm if antimicrobial therapy had a benefit.1
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were positive for chlamydia at baseline were more
likely than those who were negative to report having
been tested independently (43%, 29/67 v 24%,
229/968; P<0.001).
DISCUSSION
The risk of clinical pelvic inflammatory disease over
12 months in women screened for C trachomatis was
non-significantly reduced by 35%. The overall inci-
dence of pelvic inflammatory disease was, however,
low (1.6%). In 137 women with chlamydial infection
at baseline, 9.5% in the deferred screening control
group developed pelvic inflammatory disease com-
pared with only 1.6% in the screened group. Over
90% (67/74) of control women with chlamydial infec-
tion at baseline did not develop clinical pelvic inflam-
matory disease; and most cases (79%, 30/38) of pelvic
inflammatory disease, including 10 cases of chlamydia
positive pelvic inflammatory disease, occurred in
women who were negative for chlamydia at baseline,
suggesting these were incident infections.
Strengths and limitations of the study
This is the first trial of chlamydia screening to obtain
samples for delayed chlamydia testing from the control
women. Analysis of these samples enabled us to pro-
vide novel data on the risk of pelvic inflammatory dis-
ease in untreated women positive for chlamydia in the
community, which can now be used for modelling and
cost effectiveness studies.12 Secondly, this is the first
UK study to provide prospective data on the overall
risk of clinical pelvic inflammatory disease in a large
cohort of sexually active young women in the commu-
nity. Thirdly, this is themost robust trial to date.3 8 Ran-
domisation was done blind and after recruitment6 and
themain outcomewas assessed blind. The 94% follow-
up was a major achievement in this young, mobile,
mainly inner city population, requiring repeated tele-
phone calls and emails.We also obtained data on inde-
pendent chlamydia testing and treatment in both
groups. Participants came from a wide range of back-
grounds and included 1124 sexually active teenagers
of whom 46% came from ethnic minorities. As in the
English national chlamydia screening programme, we
used self taken samples and routine management of
infected women. Vaginal swabs are more sensitive
than urine samples for the detection of chlamydia.21
The main weakness is that despite a similar sample
size (2529 v 2607) and incidence of pelvic inflamma-
tory disease (1.6% v 1.7%) to the Scholes trial, screen-
ing twice as many women (1259 v 645) and treating
more women with chlamydial infection (67 v 44), the
trial was underpowered. The annual incidence of pel-
vic inflammatorydiseasewas less than the 3%913 19 used
in the sample size calculations, and screening did not
reduce the risk by at least 50%.4 Secondly, participants
were advised to be screened independently, and the
one in five who acted on this advice had a high preva-
lence of chlamydial infection. The rate of independent
testing reported by women in the deferred screening
group who were positive for chlamydia at baseline
was even higher (43%). It is likely that this reduced
the effect of the intervention. Thirdly, the clinical diag-
nosis of pelvic inflammatory disease lacks sensitivity22
and specificity, which is also likely to attenuate the
effect size.8 The diagnosis of pelvic inflammatory dis-
ease depended on the women seeing a health
professional,7 and the women’s reports of possible
symptoms or consultations for pelvic inflammatory
disease may be unreliable, particularly for those who
could be followed up only by telephone questionnaire
(10% of controls, 7% of screened women), and who
might tend to respond negatively to questions. We
were able to obtain detailed medical records only of
the 17% of women with potential pelvic inflammatory
disease. In addition, the medical records were some-
times incomplete and many women changed address
and general practitioner during the study period or
attended different hospitals and clinics. Finally, as
with all randomised clinical trials, the study has limited
generalisability andmay not apply to different popula-
tions such as women attending healthcare facilities,
those from different ethnic groups, higher risk
women such as sex workers, or non-UK populations.
Comparison with other studies
Only two trials have been carried out on chlamydia
screening to prevent pelvic inflammatory disease in
non-pregnant women.8 These were done in the United
States and Denmark and started in 1990 and 1997.49
The trial by Scholes et al involved 2607 women from
a health maintenance organisation.8 However, over a
third of the women (n=364) in the intervention group
were not screened, and these women had a low rate of
pelvic inflammatory disease (0.5%, 2/364) leading to a
relative risk of pelvic inflammatory disease in those
allocated to screening compared with usual care of
0.44 (95% confidence interval 0.20 to 0.90). Pelvic
inflammatory disease is polymicrobial, but in many
cases no pathogens are isolated. If chlamydial infection
is implicated in only about 30% of cases of pelvic
inflammatory disease, even if screening and treatment
prevented all cases of pelvic inflammatory disease due
to chlamydia, it would be unlikely to halve the overall
risk of pelvic inflammatory disease.8 Recently, the
Table 4 | Reported symptoms of potential pelvic inflammatory disease and sexual behaviour
over 12 months in 2057 women who completed follow-up questionnaires
Reported symptoms and
behaviour
% (No) of women
Screened women
(n=1029)
Deferred screening controls
(n=1028)
Pelvic pain 11.0 (113) 10.2 (105)
Dyspareunia 10.9 (112) 9.3 (96)
Bleedingbetweenmenstrualperiods 13.5 (139) 12.8 (132)
Abnormal vaginal discharge 15.2 (156) 13.0 (134)
Any symptom 34.0 (350) 31.3 (322)
≥2sexualpartners inpast12months 36.7 (367); n=1001 37.6 (377); n=1003
Condom use 54.5 (538); n=987 56.5 (557); n=985
Sexually transmitted infection in
past 12 months
4.8 (48); n=1007 5.2 (52); n=1000
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findings by Scholes et al have been suggested as
fortuitous.8
In a later trial in 1700 female high school students,
Ostergaard et al found that 2.1% of those in the home
sampling group and 4.2% in the usual care group
reported treatment for pelvic inflammatory disease
when interviewed after a year.9 Ascertainment of pel-
vic inflammatory diseasewas, however, unblinded and
nearly 50% of the women were lost to follow-up.8 In
addition, reports by the women might be unreliable,
as masked analysis of clinical data in our trial con-
firmed pelvic inflammatory disease in only 11 of the
21 women whose questionnaires reported that they
had had pelvic inflammatory disease. Finally, the inci-
dence of pelvic inflammatory disease in our trial was
slightly lower than the 2.3% found in similar aged
women attending English and Welsh general
practices.23 The women in our study with pelvic
inflammatory disease were assessed by doctors in gen-
itourinary medicine, and both coding and diagnosis
may be more reliable. It is, however, likely that the
incidence of pelvic inflammatory disease would be
higher in those lost to follow-up, sexually active teen-
agers aged <16, or those not in education.
Implications
This is the only chlamydia screening trial with this
design ever likely to be done in a developed country.
This is because of ethical issues with delayed chlamy-
dia testing and the widespread introduction of chlamy-
dia screening programmes. Although some evidence
shows that screening reduced rates of pelvic inflamma-
tory disease, especially in women with chlamydial
infection at baseline, the absolute number of cases pre-
vented was small. Our findings suggest that to prevent
one case of clinical pelvic inflammatory disease over
12 months, it may be necessary to screen 147 women
for chlamydial infection or to treat 13 women who are
positive for chlamydia. These numbers are greater
than previously suggested.8 11 If the incidence of pelvic
inflammatory disease inwomenwith chlamydial infec-
tion has been overestimated, and particularly if it is less
than 10%,24 then the cost effectiveness of screening
might be exaggerated.8 10
Most cases of pelvic inflammatory disease over
12 months were not prevented by a single chlamydia
screen and occurred in women who were negative for
chlamydia at baseline. This suggests the importance of
incident infection. Policymakersmight consider focus-
ing on more frequent testing of those at higher risk,
such as women with a new sexual partner or a recent
history of chlamydial infection.11 25 26
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